When measles breaks out in a setting with low routine coverage, the measles vaccine is the only intervention that stops transmission — and the speed of the response decides how many children survive. International Health Journal first reported on reactive measles vaccination as a tool for outbreak control in mortality-reduction settings, including the campaigns that followed the 2005–2006 outbreaks in the Democratic Republic of Congo. This article explains how outbreak-response immunisation works, what makes it succeed in hard-to-reach areas, and the logistics that field teams must master.
Measles: why outbreaks move so fast
Measles is among the most contagious human diseases; a single case can infect twelve to eighteen susceptible contacts. Herd protection requires roughly 95% population immunity, a threshold that conflict, displacement, and weak routine services frequently push out of reach. Once a cluster appears in an under-vaccinated community, case numbers can double within days, and complications — pneumonia, encephalitis, and death — concentrate in malnourished and very young children.
Routine immunisation versus reactive campaigns
The first line of defence is strong routine immunisation with the measles or measles-mumps-rubella (MMR) vaccine on schedule. When routine coverage has failed and an outbreak is already underway, a reactive vaccination campaign targets the affected and surrounding areas to raise immunity quickly. Evidence from mortality-reduction settings shows that a well-timed reactive campaign can shorten an outbreak and avert deaths, even when launched after the first cases — provided it reaches susceptible children fast and widely.
What the measles vaccine actually does
The live attenuated measles vaccine, given alone or as MMR, prompts durable immunity in the large majority of recipients after one dose, rising further with a second. It is safe, inexpensive, and decades-proven. In outbreak response the operational challenge is rarely the vaccine itself but delivering it intact and on time: maintaining potency depends on an unbroken cold chain from manufacturer to the child’s arm.
Cold chain: the make-or-break factor
Measles vaccine loses potency when exposed to heat or, after reconstitution, to light and time. A field campaign therefore lives or dies by its cold chain — vaccine carriers, ice packs, temperature monitors, and disciplined discarding of reconstituted vials after the recommended window. Programmes that pair every vaccination team with reliable cold-chain monitoring and solar refrigeration at the base post protect both potency and public trust.
- Plan the micro-area: map settlements, displacement camps, and missed pockets before day one.
- Protect potency: validated carriers, conditioned ice packs, electronic temperature logging.
- Reach the missed: mobile teams, outreach to nomadic and refugee groups, evening and market-day sessions.
- Measure coverage: rapid coverage surveys to find and close immunity gaps.
Reaching mobile and displaced populations
The hardest children to vaccinate are those on the move: pastoralist families, refugees, and informal-settlement residents. Lessons from field campaigns are consistent — engage community leaders early, schedule around migration and market patterns, and bring the campaign to the population rather than waiting for them to come to a fixed post. The same outreach muscle that delivers measles vaccine also strengthens routine services long after the outbreak ends.
Surveillance and confirmation
An outbreak response is only as good as the surveillance that triggers and guides it. Suspected cases need rapid reporting, and laboratory confirmation prevents wasted campaigns and misattributed rashes. Point-of-care diagnostics and a functioning field laboratory let teams confirm measles, rule out look-alikes, and direct vaccine where it counts.
Timing the campaign and choosing the target age group
Speed and scope are the two levers a response team controls. The earlier a reactive campaign launches relative to the epidemic curve, the more cases it averts — delays of even a week or two in a fast-moving outbreak translate into preventable deaths. The target age range matters just as much: in many outbreaks the burden has shifted to older children and even young adults because earlier campaigns missed them, so a rigid focus on under-fives can leave the true reservoir of susceptibles untouched. Good outbreak investigation — describing cases by age, location, and vaccination status — tells the team where to draw the boundary and which ages to include, turning a generic campaign into a targeted one.
Building trust and managing rumour
Vaccine campaigns succeed or fail on community confidence as much as on logistics. In displaced and marginalised populations, distrust of outside health teams, language barriers, and circulating rumours can collapse turnout overnight. Experience from field campaigns points to the same remedies: recruit and visibly involve respected local figures, communicate honestly about minor side effects, and respond to rumours quickly rather than ignoring them. A campaign that treats communication as a core workstream, not an afterthought, reaches the children that a purely operational push would miss.
Frequently asked questions
Is reactive vaccination effective once an outbreak has started?
Yes. In mortality-reduction settings, reactive measles campaigns launched after the first cases have been shown to shorten outbreaks and prevent deaths, especially when they reach susceptible children quickly and broadly.
How many doses of measles vaccine are needed?
One dose protects most recipients; a second dose closes the remaining gap and is the routine standard. Outbreak campaigns often vaccinate regardless of prior history to maximise coverage.
What ruins a measles campaign most often?
A broken cold chain. Heat-damaged vaccine offers no protection, so temperature control from depot to arm is the decisive operational task.
Can the measles vaccine be given safely during an outbreak?
Yes. The live attenuated measles vaccine is safe to give during outbreaks, including to children whose vaccination history is unknown. Vaccinating regardless of prior history is a standard outbreak strategy to maximise the share of protected children quickly.
How quickly does the measles vaccine protect a child?
Protective immunity develops within about two weeks of vaccination in most recipients. Because measles spreads so fast, every day saved in launching a campaign increases the number of children protected before exposure.
Equipping an outbreak response
Stopping a measles outbreak in a remote setting takes more than vaccine: it takes the cold chain to keep it potent and the diagnostics to confirm cases. See our coverage of vaccination campaign logistics and outbreak response, and the confirmation side of the work on our field-ready microscopes page. Programme buyers assembling a field laboratory and confirmation bench can review the available diagnostic equipment. Further reading is in our articles, news, and the forum.
This article is general information for health programmes and is not medical advice. Immunisation decisions should follow national and WHO guidance and qualified clinical judgement.
How reactive measles vaccination campaigns work
A reactive vaccination campaign is launched in response to a confirmed outbreak rather than on a routine schedule. Once cases cross an epidemiological threshold, teams aim to vaccinate the susceptible population in the affected area as fast as possible, because measles spreads explosively and every day widens the cohort at risk. Success hinges on field logistics: an unbroken cold chain to keep vaccine viable, rapid micro-planning of catchment areas, community mobilisation, and reliable point-of-care confirmation so effort is focused where transmission is active. In low-resource settings these same constraints — cold chain, portable diagnostics, field-ready equipment — determine whether the response keeps pace with the virus.
Related: our field diagnostics guide and LAC Medical Supplies — diagnostic equipment.